van der Graaf WT - Search Results

1

Synovial sarcoma diagnosis and management in the era of targeted therapies.

Vlenterie M, Jones RL, van der Graaf WT. Vlenterie M, et al. Among authors: van der graaf wt. Curr Opin Oncol. 2015 Jul;27(4):316-22. doi: 10.1097/CCO.0000000000000198. Curr Opin Oncol. 2015. PMID: 26049271 Review.

2

Anaplastic lymphoma kinase aberrations in rhabdomyosarcoma: clinical and prognostic implications.

van Gaal JC, Flucke UE, Roeffen MH, de Bont ES, Sleijfer S, Mavinkurve-Groothuis AM, Suurmeijer AJ, van der Graaf WT, Versleijen-Jonkers YM. van Gaal JC, et al. Among authors: van der graaf wt. J Clin Oncol. 2012 Jan 20;30(3):308-15. doi: 10.1200/JCO.2011.37.8588. Epub 2011 Dec 19. J Clin Oncol. 2012. PMID: 22184391

3

New systemic therapy options for advanced sarcomas.

van der Graaf WT, Gelderblom H. van der Graaf WT, et al. Curr Treat Options Oncol. 2012 Sep;13(3):306-17. doi: 10.1007/s11864-012-0196-2. Curr Treat Options Oncol. 2012. PMID: 22661203 Free PMC article. Review.

4

Prognostic and therapeutic relevance of the IGF pathway in Ewing's sarcoma patients.

van de Luijtgaarden AC, Versleijen-Jonkers YM, Roeffen MH, Schreuder HW, Flucke UE, van der Graaf WT. van de Luijtgaarden AC, et al. Among authors: van der graaf wt. Target Oncol. 2013 Dec;8(4):253-60. doi: 10.1007/s11523-012-0248-3. Epub 2013 Jan 6. Target Oncol. 2013. PMID: 23292309

5

Pheochromocytoma and gastrointestinal stromal tumors in patients with neurofibromatosis type I.

Vlenterie M, Flucke U, Hofbauer LC, Timmers HJ, Gastmeier J, Aust DE, van der Graaf WT, Wesseling P, Eisenhofer G, Lenders JW. Vlenterie M, et al. Among authors: van der graaf wt. Am J Med. 2013 Feb;126(2):174-80. doi: 10.1016/j.amjmed.2012.07.022. Am J Med. 2013. PMID: 23331445 Review.

6

Expression and clinical relevance of MET and ALK in Ewing sarcomas.

Fleuren ED, Roeffen MH, Leenders WP, Flucke UE, Vlenterie M, Schreuder HW, Boerman OC, van der Graaf WT, Versleijen-Jonkers YM. Fleuren ED, et al. Among authors: van der graaf wt. Int J Cancer. 2013 Jul 15;133(2):427-36. doi: 10.1002/ijc.28047. Epub 2013 Feb 25. Int J Cancer. 2013. PMID: 23335077

7

Targeting receptor tyrosine kinases in osteosarcoma and Ewing sarcoma: current hurdles and future perspectives.

Fleuren ED, Versleijen-Jonkers YM, Boerman OC, van der Graaf WT. Fleuren ED, et al. Among authors: van der graaf wt. Biochim Biophys Acta. 2014 Apr;1845(2):266-76. doi: 10.1016/j.bbcan.2014.02.005. Epub 2014 Feb 28. Biochim Biophys Acta. 2014. PMID: 24582852

8

Anti-angiogenic therapy, a new player in the field of sarcoma treatment.

Versleijen-Jonkers YM, Vlenterie M, van de Luijtgaarden AC, van der Graaf WT. Versleijen-Jonkers YM, et al. Among authors: van der graaf wt, van de luijtgaarden ac. Crit Rev Oncol Hematol. 2014 Aug;91(2):172-85. doi: 10.1016/j.critrevonc.2014.02.001. Epub 2014 Feb 15. Crit Rev Oncol Hematol. 2014. PMID: 24613529 Review.

9

Solitary fibrous tumor - clinicopathologic, immunohistochemical and molecular analysis of 28 cases.

Vogels RJ, Vlenterie M, Versleijen-Jonkers YM, Ruijter E, Bekers EM, Verdijk MA, Link MM, Bonenkamp JJ, van der Graaf WT, Slootweg PJ, Suurmeijer AJ, Groenen PJ, Flucke U. Vogels RJ, et al. Among authors: van der graaf wt. Diagn Pathol. 2014 Nov 29;9:224. doi: 10.1186/s13000-014-0224-6. Diagn Pathol. 2014. PMID: 25432794 Free PMC article.

10

Promising management of pazopanib-induced liver toxicity.

Vlenterie M, van Erp NP, van der Graaf WT. Vlenterie M, et al. Among authors: van der graaf wt, van erp np. Acta Oncol. 2015 Jul;54(7):1064-6. doi: 10.3109/0284186X.2015.1004368. Epub 2015 Mar 3. Acta Oncol. 2015. PMID: 25734660 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

638 results

Search Page

Filters